Oliver Flossmann

TL;DR: The new version of Birmingham Vasculitis Activity score (v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein and is repeatable, reproducible and sensitive to change.

TL;DR: Patients with ANCA-associated vasculitis treated with conventional regimens are at increased risk of death compared with an age- and sex-matched population.

TL;DR: Recommendations for conducting clinical trials in AAV deal with the following areas related to clinical studies of vasculitis: definitions of disease, activity states, outcome measures, eligibility criteria, trial design including relevant end points, and biomarkers.

TL;DR: A systematic literature review as a background to the European League Against Rheumatism recommendations for conducting clinical trials in anti-neutrophil cytoplasm antibody associated vasculitis (AAV) found methodological variations between studies highlight the need for a consensus on terminology and definitions for future conduct of clinical studies in AAV.

TL;DR: Pulse cyclophosphamide is associated with a higher relapse risk than DO cycloph phosphamide, however, this is not associated with increased mortality or long-term morbidity.